Dermatology

The AJMC^® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

December 16th 2024

FDA Approves Tapinarof Cream 1% for Patients With Atopic Dermatitis

By Brooke McCormick

November 21st 2024

Collaborating for Cancer Care Equity: Community and Academic Insights

By Maggie L. Shaw

September 25th 2024

Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients

By Brooke McCormick

September 24th 2024

Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

By Cameron Santoro

September 17th 2024

Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color

By Brooke McCormick

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

Video Series

August 5th 2024

Optimizing Multidisciplinary Care of Patients with Hidradenitis Suppurativa

August 5th 2024

The Role of Surgery in Hidradenitis Suppurativa

July 29th 2024

Managing Pain in Patients with Hidradenitis Suppurativa

July 29th 2024

Ongoing Research in Hidradenitis Suppurativa

July 22nd 2024

Recent Data on Bimekizumab for Hidradenitis Suppurativa

July 22nd 2024

Biologic Therapies for Hidradenitis Suppurativa

July 15th 2024

The Role of Treatment Guidelines for HS

July 15th 2024

Hidradenitis Suppurativa (HS): Staging Considerations and Unmet Needs

July 8th 2024

The Impact of Hidradenitis Suppurativa on Families

July 8th 2024

Hidradenitis Suppurativa: Addressing the Psychosocial Impact and Hospitalization Rate

Video Interviews

August 20th 2024

Patient Education, Provider Education, and Overall Final Thoughts

August 13th 2024

Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment

August 13th 2024

The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment

August 7th 2024

Dr Steve Feldman on How Adverse Event Risks Influence Atopic Dermatitis Treatment Selection

August 6th 2024

Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

August 6th 2024

Addressing Persistent Symptoms in Chronic Spontaneous Urticaria: Beyond IgE-Targeted Treatments

August 3rd 2024

Dr Steve Feldman: Dupilumab Has Become the "Gold Standard" for Atopic Dermatitis Treatments

July 30th 2024

Dr Steve Feldman: New Atopic Dermatitis Treatments Effective in Managing Inflammation, Alleviating Itch

July 16th 2024

Timothy Caulfield on Enhancing Information Dissemination in Pediatric Dermatology

June 5th 2024

Dr Thomas Hall Explores How Geographic, Socioeconomic Factors Affect Dermatological Outcomes

Continuing Medical Education

December 25th 2024

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology

December 25th 2024

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Silhouettes of different skin colors | Image Credit: freshidea - stock.adobe.com

September 17th 2024

Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials

Brooke McCormick

Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.

FDA approved stamp | Image Credit: Olivier Le Moal - stock.adobe.com

September 16th 2024

FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis

Brooke McCormick

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Image Credit: Andrew Popov - stock.adobe.com

September 13th 2024

Experts Highlight New Dermatological Treatments, Importance of Clinical Trial Diversity

Brooke McCormick

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and emphasized the importance of clinical trial diversity.

hands of a patient with vitiligo | Image Credit: Rabizo Anatolii - stock.adobe.com

September 5th 2024

Patients With Vitiligo Experience Poorer Quality of Life but Greater Health Care Access, Utilization

Brooke McCormick

Compared with those without vitiligo, patients with vitiligo have higher health care access and utilization but report a lower quality of life.

AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com

August 28th 2024

Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy

Cameron Santoro Brooke McCormick

Kristen Whitney, DO, FAAD, dermatologist within the Allegheny Health Network, discusses advancements in dermoscopy, predicting that emerging technologies and artificial intelligence (AI) will improve dermatologists' efficiency in monitoring and diagnosing skin conditions.

Woman with vitiligo covering face with her hands | Image Credit: Savory - stock.adobe.com

August 19th 2024

Vitiligo, Mental Health Tied to Higher Health Care Utilization and Costs

Brooke McCormick

Patients with vitiligo and psychosocial comorbidities face significantly higher overall health care utilization and costs, although their vitiligo-related expenditures remain similar to those without such comorbidities.

FDA approval | Image Credit: BHM - stock.adobe.com

August 13th 2024

FDA Approves Nemolizumab for Adult Patients With Prurigo Nodularis

Brooke McCormick

The FDA has approved nemolizumab (Nemluvio; Galderma) to treat patients with prurigo nodularis based on successful phase III trials demonstrating significant reductions in itch and sleep disturbances.

Child scratching arm | Image credit: cunaplus - stock.adobe.com

August 12th 2024

Corticosteroids vs Noncorticosteroids in Pediatric Dermatology: Challenges and Considerations

Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering the specific needs and risks of each child.

Guselkumab | Image credit: luchschenF - stock.adobe.com

August 6th 2024

Extended Guselkumab Dosing Every 16 Weeks Proven Effective for Psoriasis Maintenance

This new study confirms the noninferiority of extended dosing intervals for psoriasis control in super responders.

Dermatologists examine hair loss. | Image Credit: Cienpies Design - stock.adobe.com

August 1st 2024

Research Explores Novel Insights on Pediatric Hair Loss

Cameron Santoro

Posters presented at the Society for Pediatric Dermatology Annual Meeting shed new light on pediatric hair loss, including the rising prevalence of androgenetic alopecia in children, the potential of artificial intelligence to assess hair loss severity, and the long-term safety of ritlecitinib for treating alopecia areata in adolescents.

Trichologist examines child scalp. | Image Credit: Nadzeya - stock.adobe.com

July 24th 2024

Exploring Comorbidities, Dupilumab Treatment in Pediatric Alopecia Areata

Cameron Santoro

Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis.

Man with atopic dermatitis on his hands | Image Credit: Ольга Тернавская

July 19th 2024

Long-Term Oral Corticosteroid Use Linked to Adverse Event Risk in Atopic Dermatitis

Brooke McCormick

Patients with atopic dermatitis who use oral corticosteroids for more than 90 days have a slightly increased risk of adverse events like myocardial infarction and hyperlipidemia.

Girl scratching itch | Image credit: kwanchaichaiudom - stock.adobe.com

July 18th 2024

SPD Annual Meeting Covered All Facets of Pediatric Dermatology

Julia Bonavitacola

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

Science article writing composition. | Image Credit: Macrovector - stock.adobe.com

July 18th 2024

New Study Suggests Alopecia After COVID-19 Vaccine Rare but Possible

Cameron Santoro

A literature review found a link between COVID-19 vaccination and alopecia, with most cases experiencing hair loss within 1 month after the first dose. However, the small sample size and limited data call for further investigation.

Dosage and immunosuppression should be taken into account when biologics are used for children with different skin conditions | Image credit: Марина Терехова - stock.adobe.com

July 15th 2024

Using Biologic Therapies Safely in Pediatric Patients With Skin Conditions

Julia Bonavitacola

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Hidradenitis suppurativa | Image credit: Lea - stock.adobe.com

July 15th 2024

Hidradenitis Suppurativa Causes Psychosocial Impact in Children

Julia Bonavitacola

Posters presented at the Society for Pediatric Dermatology Annual Meeting found that pediatric deroofing can lead to patient satisfaction later in life.

Topical therapy | Image credit: Victor Moussa - stock.adobe.com

July 14th 2024

Ways to Use Nonsteroidal Topical Therapies in the Treatment of Skin Conditions

Julia Bonavitacola

Updates in nonsteroidal topical therapies were presented during a session at the Society for Pediatric Dermatology Annual Meeting.

ChatGPT | Image credit: Timon - stock.adobe.com

July 13th 2024

Can ChatGPT Replace Doctors? Generative AIs Provide New Tool in Dermatology

Julia Bonavitacola

A presentation at the Society for Pediatric Dermatology Annual Conference discussed how to use generative artificial intelligence (AI) to improve processes while working in the dermatology space.

Debate | Image credit: Right 3 - stock.adobe.com

July 12th 2024

Friendly Debates Spark Discussion on Infantile Hemangioma, Vitiligo, and Atopic Dermatitis

Julia Bonavitacola

The Society for Pediatric Dermatology (SPD) Annual Meeting featured a new debates segment where experts in the field discussed preferred strategies for the treatment of pediatric skin conditions.

Child with vitiligo | Image credit: ChayTee - stock.adobe.com

July 12th 2024

Ruxolitinib Cream Dose Safe, Effective in Children With Atopic Dermatitis, Vitiligo

Julia Bonavitacola

Twice-daily application of 1.5% ruxolitinib cream was found to be effective in children and adolescents with atopic dermatitis and vitiligo.

FDA approval | Image Credit: Olivier Le Moal - stock.adobe.com

July 9th 2024

FDA Approves Roflumilast for Patients 6 Years and Older With Atopic Dermatitis

Brooke McCormick

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older.

Female patient with vitiligo | Image Credit: shurkin_son - stock.adobe.com

July 9th 2024

Study Finds Patients With Vitiligo at Higher Risk for Rheumatoid Arthritis, Systemic Lupus Erythematosus

Brooke McCormick

Patients with vitiligo have a higher genetic risk of developing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Child rash | Image credit: Piman Khrutmuang - stock.adobe.com

July 8th 2024

Society for Pediatric Dermatology Annual Meeting Sets Focus on Topical Treatments, Technology

Julia Bonavitacola

The annual meeting will take place in Toronto July 11-15, 2024.

Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa

July 1st 2024

Comorbidities and Coordinating Care Between Specialists in Hidradenitis Suppurativa

Iltefat Hamzavi, MD

Iltefat Hamzavi, MD, outlines comorbidities associated with hidradenitis suppurativa and discusses best practices for coordinating care between specialists.

Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa

July 1st 2024

Overview of the Hurley Staging System for Hidradenitis Suppurativa

Iltefat Hamzavi, MD

An expert on hidradenitis suppurativa describes the characteristics for each of the 3 stages in the Hurley staging system and how they inform treatment decisions.

Young black woman with hair concern| Image Credit: Prostock-studio-stock.adobe.com

July 1st 2024

Survey Shows Suboptimal Comfort in Treating Hair Among Patients With SOC

AJMC Contributor

In addition to ensuring residency programs provide educational and practical opportunities for addressing skin of color (SOC) hair-related concerns, prioritizing having residents of diverse backgrounds can help close knowledge and comfort gaps, suggest researchers.

patient with vitiligo covering her face with her hands | Image Credit: Savory - stock.adobe.com

June 28th 2024

Study Finds Israeli Patients With Vitiligo at Lower Risk for Parkinson Disease

Brooke McCormick

Israeli patients with vitiligo exhibit a significantly reduced risk of developing Parkinson disease (PD).

A dermatologist wearing gloves examines the skin of a sick patient. Examination and diagnosis of skin diseases-allergies, psoriasis, eczema, dermatitis | Image credit: © fusssergei - stock.adobe.com

June 26th 2024

Researchers Explore Deeper Connection Between AD, Food Allergy

AJMC Contributor

With an emerging hypothesis that inflammation of the skin prompts intestinal remodeling through various mechanisms, researchers explored the role of inflammatory signals, microbiome alterations, metabolites, and the nervous system.

Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa

June 24th 2024

Differential Diagnosis When Considering Hidradenitis Suppurativa in a Patient

Iltefat Hamzavi, MD

A dermatologist provides clinical insights on differential diagnosis strategies when considering hidradenitis suppurativa in patients and the challenges associated with diagnosis.

Iltefat Hamzavi, MD, an expert on hidradenitis suppurativa

June 24th 2024

The Pathophysiology of Hidradenitis Suppurativa

Iltefat Hamzavi, MD

Iltefat Hamzavi, MD, describes the pathophysiology of hidradenitis suppurativa and associated comorbidities that are commonly seen in patients.

1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions